Fulgent Genetics (FLGT) Short term Debt (2020 - 2026)

Fulgent Genetics has disclosed Short term Debt across 7 years of filings, most recently posting $30.6 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $30.6 million, up 10.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.6 million (up 10.56% YoY), and the FY2025 annual result was $28.1 million, up 1.94% from the prior year.
• Short term Debt came in at $30.6 million for Q1 2026 at Fulgent Genetics, up from $28.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $30.6 million in Q1 2026 to a low of $10.9 million in Q4 2022.
• The 5-year median for Short term Debt is $26.9 million (2024), against an average of $23.0 million.
• Across the five-year window, Short term Debt jumped 4945.12% in 2022 and tumbled 50.07% in 2023, its largest moves.
• Fulgent Genetics' Short term Debt stood at $10.9 million in 2022, then soared by 108.35% to $22.7 million in 2023, then rose by 21.63% to $27.6 million in 2024, then climbed by 1.94% to $28.1 million in 2025, then increased by 8.79% to $30.6 million in 2026.
• The last three Short term Debt figures came in at $30.6 million (Q1 2026), $28.1 million (Q4 2025), and $28.5 million (Q3 2025), per Business Quant data.